Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00584
|
|||||
Drug Name |
Amprenavir
|
|||||
Synonyms |
(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide; AMV; Agenerase; Agenerase (TM); Agenerase (TN); Amprenavir (JAN/USAN/INN); Amprenavir [USAN]; Amprenavir[usan]; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin(HHA); DRG-0258; GNA & Amprenavir; HHA & Amprenavir; KVX-478; Prozei; Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; VX 478; VX-478; VX478; Vertex; Vertex VX478; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Human immunodeficiency virus infection [ICD11: 1C62.Z] | Approved | [1] | |||
Therapeutic Class |
Anti-HIV Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C25H35N3O6S
|
|||||
Canonical SMILES |
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
|
|||||
InChI |
InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1
|
|||||
InChIKey |
YMARZQAQMVYCKC-OEMFJLHTSA-N
|
|||||
CAS Number |
CAS 161814-49-9
|
|||||
Pharmaceutical Properties | Molecular Weight | 505.6 | Topological Polar Surface Area | 140 | ||
Heavy Atom Count | 35 | Rotatable Bond Count | 12 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 8 | |||
XLogP |
2.9
|
|||||
PubChem CID | ||||||
PubChem SID |
10286
, 103179760
, 104178998
, 104253275
, 104332645
, 104829267
, 11528777
, 117549941
, 118048728
, 12014852
, 125267472
, 125310993
, 127310203
, 127310204
, 127310205
, 14835820
, 14884574
, 26697364
, 29215412
, 3727052
, 3727059
, 43121862
, 46392146
, 46393211
, 46507537
, 53790789
, 57315242
, 601727
, 628182
, 71821412
, 74965413
, 7847958
, 7885327
, 7978703
, 8030478
, 8189448
, 822019
, 85177028
, 85177034
, 85177055
, 92309266
, 93166556
, 97857368
, 99239834
, 99239838
, 99239842
, 99239846
, 99239847
, 99239854
, 99239856
|
|||||
ChEBI ID |
ChEBI:40050
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
References | ||||||
1 | Fosamprenavir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.